Central Retinal Artery Occlusion: Local Intra-arterial Fibrinolysis versus Conservative Treatment, a Multicenter Randomized Trial

被引：239

作者：

Schumacher, Martin ^{[1
]}

Schmidt, Dieter ^{[2
]}

Jurklies, Bernhard ^{[5
]}

Gall, Christine ^{[3
]}

Wanke, Isabel ^{[4
]}

Schmoor, Claudia ^{[3
]}

Maier-Lenz, Herbert ^{[1
]}

Solymosi, Laszlo ^{[6
]}

Brueckmann, Hartmut ^{[7
]}

Neubauer, Aljoscha S. ^{[8
]}

Wolf, Armin ^{[8
]}

Feltgen, Nicolas ^{[9
]}

机构：

[1] Univ Freiburg, Clin Neuroradiol, D-79106 Freiburg, Germany

[2] Univ Freiburg, Dept Ophthalmol, D-79106 Freiburg, Germany

[3] Univ Freiburg, Clin Trials Ctr, D-79106 Freiburg, Germany

[4] Univ Essen Gesamthsch, Dept Neuroradiol, Essen, Germany

[5] Univ Essen Gesamthsch, Dept Ophthalmol, Essen, Germany

[6] Univ Wurzburg, Dept Neuroradiol, D-97070 Wurzburg, Germany

[7] Univ Munich, Dept Neuroradiol, D-80539 Munich, Germany

[8] Univ Munich, Dept Ophthalmol, D-80539 Munich, Germany

[9] Univ Gottingen, Dept Ophthalmol, D-3400 Gottingen, Germany

来源：

OPHTHALMOLOGY | 2010年 / 117卷 / 07期

关键词：

ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; VISUAL-ACUITY; INTRAVENOUS THROMBOLYSIS; RECANALIZATION; METAANALYSIS; OBSTRUCTION; PROGNOSIS; OUTCOMES; LYSIS;

D O I：

10.1016/j.ophtha.2010.03.061

中图分类号：

R77 [眼科学];

学科分类号：

100212 [眼科学];

摘要：

Purpose: The reported outcomes of central retinal artery occlusion (CRAO) with or without treatment vary considerably. Although local intra-arterial fibrinolysis (LIF) using recombinant tissue plasminogen activator (rtPA) is a promising treatment, outcomes have not been compared in randomized trials. Design: Prospective randomized multicenter clinical trial (the European Assessment Group for Lysis in the Eye Study) to compare treatment outcome after conservative standard treatment (CST) and LIF for acute nonarteritic CRAO. Participants: Between 2002 and 2007, 9 centers in Austria and Germany recruited 84 patients (40 received CST, 44 received LIF), and data for 82 patients were analyzed. Methods: Patients (age 18-75 years) with CRAO, symptoms for 20 hours or less, and best-corrected visual acuity (BCVA) < 0.5 logarithm of the minimum angle of resolution (logMAR) were randomized to the CST or LIF group. Main Outcome Measures: The primary end point was BCVA after 1 month; the secondary end point was safety. Results: The mean interval between first symptoms and therapy was 10.99 +/- 5.49 hours (CST) and 12.78 +/- 5.77 hours (LIF). The mean BCVA (logMAR) improved significantly in both groups (CST: -0.44 [standard deviation 0.55]; LIF: -0.45 [standard deviation 0.55]; both P < 0.0001) and did not differ between groups (P=0.69). Clinically significant visual improvement (>= 0.3 logMAR) was noted in 60.0% (CST) and 57.1% (LIF) of patients. Two patients in the CST group (4.3%) and 13 patients in the LIF group (37.1%) had adverse reactions. Because of apparently similar efficacy and the higher rate of adverse reactions in the LIF group, the study was stopped after the first interim analysis at the recommendation of the data and safety monitoring committee. Conclusions: In light of these 2 therapies' similar outcomes and the higher rate of adverse reactions associated with LIF, we cannot recommend LIF for the management of acute CRAO. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2010; 117: 1367-1375 (C) 2010 by the American Academy of Ophthalmology.

引用

页码：1367 / U128

页数：10

共 41 条

[1]

Guidelines for the early management of adults with ischemic stroke - A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups [J].